 |
67 Companies | 59 Products |
|
|
59 Products | |
344 Diseases | |
342 Trials |  |
12240 News |  |
| «12...2122232425262728293031...229230» |
- | LY294002 / Eli Lilly
Journal, IO biomarker: DSC2 suppresses the growth of gastric cancer through the inhibition of nuclear translocation of ?-catenin and PTEN/PI3K/AKT signaling pathway. (Pubmed Central) - Jul 31, 2023
Our finding suggests that DSC2 might be a potential therapeutic target for the treatment of cancers, most especially GC.
- | Aliqopa (copanlisib) / Bayer
Journal: P300 increases CSNK2A1 expression which accelerates colorectal cancer progression through activation of the PI3K-AKT-mTOR axis. (Pubmed Central) - Jul 31, 2023
The PI3K inhibitor BAY-806946 could reverse the increase in p-AKT-S473/AKT, p-AKT-T308/AKT, p-mTOR/mTOR induced by CSNK2A1 overexpression and suppress CRC cell migration and invasion. In conclusion, we report a positive feedback mechanism through which P300 enhances CSNK2A1 expression and accelerates CRC progression through the activation of the PI3K-AKT-mTOR axis.
- | Preclinical, Journal: 17-DMAG ameliorates neuroinflammation and BBB disruption via SOX5 mediated PI3K/Akt pathway after intracerebral hemorrhage in rats. (Pubmed Central) - Jul 30, 2023
These positive effects are attributed to the regulation of SOX5 and activation of the PI3K/Akt pathway. These findings highlight the possibility of targeting SOX5 and the PI3K/Akt pathway as a novel therapeutic approach for ICH.
- | Preclinical, Journal: Social memory in female mice is rapidly modulated by 17?-estradiol through ERK and Akt modulation of synapse formation. (Pubmed Central) - Jul 29, 2023
While ERK and PI3K are both required for E2 facilitation of short-term social memory and synapse formation, only ERK is required for synapse elimination. This demonstrates previously unknown, bidirectional, rapid actions of E2 on brain and behavior and underscores the importance of estrogen signaling in the brain to social behavior.
- | Journal: San Jie Tong Mai Fang (SJTMF) protects against atherosclerosis progression by regulating macroautophagy via the PI3K/AKT/mTOR signalling pathway. (Pubmed Central) - Jul 28, 2023
Taken together, these findings indicate that SJTMF may regulate the polarization of macrophages by inhibiting the PI3K/AKT/mTOR signaling pathway, thereby reducing atherosclerotic plaque damage in ApoE-/- mice, thereby, promoting macrophage autophagy and eliciting a significant anti-arteriosclerosis effect. Hence, SJTMF may represent a promising new candidate drug for the treatment of atherosclerosis.
- | ethambutol / Generic mfg.
Journal: Protease-Activated Receptor-2 and Phospholipid Metabolism Analysis in Hyperuricemia-Induced Renal Injury. (Pubmed Central) - Jul 28, 2023
We induced a hyperuricemia model in rats by adenine and ethambutol gavage in an in vivo experiment...Our work suggests that PAR2 may mediate hyperuricemia-mediated renal injury by activating the PI3K/AKT/NF-?B pathway. The PAR2 antagonist AZ3451 may be a promising therapeutic strategy for hyperuricemia-induced inflammatory responses.
- | parsaclisib (INCB50465) / Incyte
Trial completion date: CITADEL-203: A Study of INCB050465 in Relapsed or Refractory Follicular Lymphoma (clinicaltrials.gov) - Jul 28, 2023
P2, N=126, Active, not recruiting, Sponsor: Incyte Corporation
The PAR2 antagonist AZ3451 may be a promising therapeutic strategy for hyperuricemia-induced inflammatory responses. Trial completion date: Jun 2023 --> Jul 2024
- | LY294002 / Eli Lilly
Journal: Secreted phosphoprotein 1 exacerbates renal ischemia-reperfusion injury by inhibiting PI3K/AKT signaling pathway. (Pubmed Central) - Jul 28, 2023
In vitro and in vivo studies revealed an increase in cell apoptosis due to SPP1 overexpression, but the opposite is true when SPP1 is silenced. SPP1 downregulation led to high p-PI3K and p-AKT protein levels, and the LY294002 application inhibited SPP1 inhibition-mediated anti-apoptotic effect Taken together, SPP1 exacerbates renal IRI in vivo and in vitro via promoting programmed cell death by inhibiting PI3K/AKT signaling pathway.
- | Synribo (omacetaxine mepesuccinate) / Teva
Journal: Repurposing a plant alkaloid homoharringtonine targets insulinoma associated-1 in N-Myc-activated neuroblastoma. (Pubmed Central) - Jul 28, 2023
Taken together, the suppression of the INSM1-associated signaling pathway axis promotes the inhibition of NB tumor cell growth. This study developed a feasible approach for repurposing an effective anti-NB drug.
- Opdivo (nivolumab) / Ono Pharma, BMS, Aliqopa (copanlisib) / Bayer
NCI10221: Phase II multicenter biomarker driven combination trial of copanlisib and nivolumab in patients with molecularly-selected advanced solid tumors (BaCoN) () - Jul 27, 2023 - Abstract #ESMO2023ESMO_2274;
P1/2
Conclusions The combination of copanlisib and nivolumab is well tolerated with antitumor activity in pts with PIK3CA hotspot and PTEN mutations including PD-1/L1i-exposed pts. Translational analyses are ongoing.
- Checkpoint inhibitors and Pi3K inhibitors (Granada Auditorium - Hall 3) - Jul 27, 2023 - Abstract #ESMO2023ESMO_1294;
- CDK4/6 and PI3K Inhibitors in Management of Advanced Breast Cancer () - Jul 26, 2023 - Abstract #MOGAASM2023MOGA_ASM_20;
- | Preclinical, Journal: Efficacy of combined targeted therapy with PI3K and CDK4/6 or PARP and WEE1 inhibitors in neuroblastoma cell lines. (Pubmed Central) - Jul 25, 2023
Moreover, combining MK?1775 and BMN673 decreased the numbers of cells in S phase to a greater extent than either drug alone, while when combining PD?0332991 and BYL719 the observed effect was close to that of PD?0332991 alone. To summarize, PI3K and CDK4/6 or PARP and WEE1 exhibited synergistic anti?NB effects and lower doses of the inhibitors could be utilized, thereby potentially reducing adverse side effects.
- | Journal: Propofol inhibits colon cancer cell stemness and epithelial-mesenchymal transition by regulating SIRT1, Wnt/?-catenin and PI3K/AKT/mTOR signaling pathways. (Pubmed Central) - Jul 25, 2023
Propofol inhibits LOVO and SW480 cell stemness and EMT by regulating SIRT1 and the Wnt/?-catenin and PI3K/AKT/mTOR signaling pathways. Our findings indicate that propofol inhibits SIRT1 in cancer and is advantageous in colon cancer surgical treatment of patients with high SIRT1 expression.
- || Zydelig (idelalisib) / Gilead, Aliqopa (copanlisib) / Bayer
Retrospective data, Review, Journal: Phosphatidylinositol 3 kinase inhibitor-related pneumonitis: a systematic review and meta-analysis. (Pubmed Central) - Jul 25, 2023
PI3K inhibitors significantly increased the risk of pneumonitis compared with controls, and most cases are severe or even life-threatening. CRD42022318878.
- Piqray (alpelisib) / Novartis
Sensitization of Cancer Cells to Tumor Treating Fields (TTFields) via Inhibition of the PI3K/AKT Signaling Pathway (Exhibit Hall) - Jul 25, 2023 - Abstract #IASLCWCLC2023IASLC_WCLC_1998;
CRD42022318878. The PI3K/AKT signaling pathway is involved in reduced sensitivity of cancer cells to TTFields treatment, and PI3K inhibition may allow sensitization to TTFields.
- SOX2 Deregulated Squamous Carcinomas Are Vulnerable to AKT3 Inhibition (Exhibit Hall) - Jul 25, 2023 - Abstract #IASLCWCLC2023IASLC_WCLC_1212;
The PI3K/AKT signaling pathway is involved in reduced sensitivity of cancer cells to TTFields treatment, and PI3K inhibition may allow sensitization to TTFields. Taken together, our work suggests that SOX2-amplified squamous cancers may be vulnerable to isoform-specific inhibition of AKT3.
- | Journal: Renoprotective Effect of Isoorientin in Diabetic Nephropathy via Activating Autophagy and Inhibiting the PI3K-AKT-TSC2-mTOR Pathway. (Pubmed Central) - Jul 25, 2023
The protective effect of ISO and its effects on autophagy and particularly on mitophagy were further proved using a DN mice model. To summarize, our study identified the protective effects of ISO against DN and demonstrated that ISO was a strong activator of autophagy, which could provide a basis for drug development.
- | serabelisib (MLN1117) / Takeda
Journal: Serabelisib regulates GSDMD-mediated pyroptosis, apoptosis and migration of hepatoma cells via the PI3K/Akt/E-cadherin signaling pathway. (Pubmed Central) - Jul 24, 2023
To summarize, our study identified the protective effects of ISO against DN and demonstrated that ISO was a strong activator of autophagy, which could provide a basis for drug development. Serabelisib inhibited the PI3K/AKT signaling pathway, thereby inhibiting EMT and promoting apoptosis and pyroptosis in HepG2 and HuH-6 cells.
- || Review, Journal: Exploring the potential of treating chronic liver disease targeting the PI3K/Akt pathway and polarization mechanism of macrophages. (Pubmed Central) - Jul 24, 2023
Conversely, inhibiting PI3K/Akt signaling could enhance the M1-like phenotype, which exacerbates liver damage. Targeting the PI3K/Akt pathway has tremendous potential as a therapeutic strategy for regulating macrophage polarization and activity to treat chronic liver diseases with plant chemicals, providing new avenues for liver disease treatment.
- || Retrospective data, Review, Journal, Metastases, Discordant: Discordance of PIK3CA mutational status between primary and metastatic breast cancer: a systematic review and meta-analysis. (Pubmed Central) - Jul 24, 2023
Targeting the PI3K/Akt pathway has tremendous potential as a therapeutic strategy for regulating macrophage polarization and activity to treat chronic liver diseases with plant chemicals, providing new avenues for liver disease treatment. Our results indicate the need of obtaining metastatic biopsies for PIK3CA-mutation analysis and the possibility of testing of the primary tumor, in case a re-biopsy deemed non-feasible.
- | chloroquine phosphate / Generic mfg.
Journal: 1,8-Cineole ameliorates endothelial injury and hypertension induced by L-NAME through regulation of autophagy via PI3K/mTOR signaling pathway. (Pubmed Central) - Jul 24, 2023
The addition of autophagy inhibitor CQ increases the expression of eNOS. Taken together, our results indicate that 1,8-Cineole has potential beneficial promising antihypertension depending on the integrity of vascular endothelial structure and function induced by L-NAME, and the mechanism involves ameliorating autophagy by regulatiing of PI3K/mTOR.
- | Journal, IO biomarker: Synthetic phenolic antioxidants evoked hepatoxicity in grass carp (Ctenopharyngodon idella) through modulating the ROS-PI3K/mTOR/AKT pathway: Apoptosis-autophagy crosstalk. (Pubmed Central) - Jul 24, 2023
In summary, our findings demonstrated that BHA and BHT exposure could induce liver damage induced via regulating ROS/PI3K-mediated autophagic hyperactivation, which is a crucial step in triggering hepatocyte death. This study provides novel insight into the potential mechanisms underlying liver damage caused by BHA and BHT in aquatic organisms, and offers a new theoretical basis for ecological risk assessment of SPAs.
- | Journal: Lycopene abolishes typical polyhalogenated carbazoles (PHCZs)-induced hepatic injury in yellow catfish (Pelteobagrus fulvidraco): Involvement of ROS/PI3K-AKT/NF-?B signaling. (Pubmed Central) - Jul 24, 2023
In contrast, LYC treatment could alleviate the 3,6-DCCZ-induced pathological changes, hepatic ROS accumulation, autophagy, inflammatory response and apoptosis. To sum up, this study provided the demonstration that LYC exerts hepatoprotective effects to alleviate 3,6-DCCZ-induced liver damage by inihibiting ROS/PI3K-AKT/NF-?B signaling in yellow catfish.
- | LY294002 / Eli Lilly
Journal: Cyp2e1 knockdown attenuates high glucose-induced apoptosis and oxidative stress of cardiomyocytes by activating PI3K/Akt signaling. (Pubmed Central) - Jul 24, 2023
Cyp2e1 knockdown attenuated HG-induced apoptosis and oxidative stress by activating PI3K/Akt signaling in cardiomyocytes. These findings suggested that Cyp2e1 might be potentially used as an effective therapeutic strategy for DCM.
- | Journal: Saffron Petal, an Edible Byproduct of Saffron, Alleviates Dextran Sulfate Sodium-Induced Colitis by Inhibiting Macrophage Activation and Regulating Gut Microbiota. (Pubmed Central) - Jul 21, 2023
In parallel, SP extract also effectively corrected microbial dysbiosis by increasing the abundance of Bacteroides acidifaciens, Bacteroides vulgatus, Lactobacillus murinus, and Lactobacillus gasseri. These findings indicate that the effectiveness of SP extract in treating colitis is demonstrated by its ability to reduce macrophage activation, inhibit the PI3K/Akt and MAPK pathways, and regulate gut microbiota, suggesting that SP extract holds great potential as a therapeutic option for colitis.
- | Journal: Qizhi Jiangtang capsule activates podocyte autophagy in diabetic kidney disease by inhibiting phosphatidylinositol 3-kinase/protein kinase B/mammalian target of rapamycin pathways. (Pubmed Central) - Jul 20, 2023
These findings indicate that the effectiveness of SP extract in treating colitis is demonstrated by its ability to reduce macrophage activation, inhibit the PI3K/Akt and MAPK pathways, and regulate gut microbiota, suggesting that SP extract holds great potential as a therapeutic option for colitis. These results showed that the QZJT can enhance podocyte autophagy and ameliorate podocyte injury in DKD by inhibiting the PI3K/AKT/mTOR signaling pathway.
- | parsaclisib (INCB50465) / Incyte
Trial completion date, Trial primary completion date: Open-Label Study of Parsaclisib, in Japanese Participants With Relapsed or Refractory Follicular Lymphoma (CITADEL-213) (clinicaltrials.gov) - Jul 20, 2023
P2, N=42, Active, not recruiting, Sponsor: Incyte Biosciences Japan GK
These results showed that the QZJT can enhance podocyte autophagy and ameliorate podocyte injury in DKD by inhibiting the PI3K/AKT/mTOR signaling pathway. Trial completion date: Feb 2024 --> Oct 2023 | Trial primary completion date: Feb 2024 --> Feb 2023
- | Journal: The mechanisms of class 1A PI3K and Wnt/?-catenin coupled signaling in breast cancer. (Pubmed Central) - Jul 20, 2023
However, PI3K exhibits opposing effects on Wnt/?-catenin signaling in distinct tumor subsets, whereby PI3K promotes Wnt/?-catenin activation in ER+ cancers, but paradoxically suppresses this pathway in ER- breast cancers. This review discusses the molecular mechanisms for PI3K-Wnt crosstalk in breast cancer, and how Wnt-targeted therapies have the potential to contribute to treatment regimens for breast cancers with PI3K dysregulation.
- sorafenib / Generic mfg.
Sorafenib Combined with Dickkopf-1 Inhibitor Synergistically Inhibited PI3K/Akt and Wnt/?-Catenin Signaling Pathways in Hepatocellular Carcinoma () - Jul 20, 2023 - Abstract #APPLE2023APPLE_369;
in HCC. These findings indicated that inhibition of DKK1 might be a novel therapeutic strategy in HCC.
- | Piqray (alpelisib) / Novartis
Journal: The effect of the alpha-specific PI3K inhibitor alpelisib combined with anti-HER2 therapy in HER2+/PIK3CA mutant breast cancer. (Pubmed Central) - Jul 20, 2023
Our findings support the use of an alpha-selective PI3K inhibitor to overcome the therapeutic limitations associated with single or dual HER2 blockade in PIK3CA-mutant HER2+ breast cancer. Future studies are warranted to confirm the potential role of candidate genes/pathways in resistance to alpelisib.
- | Keytruda (pembrolizumab) / Merck (MSD)
Journal, PD(L)-1 Biomarker, IO biomarker: Targeting PI3K? increases the efficacy of anti-PD-1 antibody in cervical cancer. (Pubmed Central) - Jul 20, 2023
The efficacy of PI3K? inhibitors combined with PD-1 antibodies is promising in cervical cancer and warrants additional clinical and mechanistic investigations.
- | dactolisib (RTB101) / Adicet Bio
Journal: Discovery of N-(2-chloro-5-(3-(pyridin-4-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl)pyridin-3-yl)-4-fluorobenzenesulfonamide (FD274) as a highly potent PI3K/mTOR dual inhibitor for the treatment of acute myeloid leukemia. (Pubmed Central) - Jul 19, 2023
inhibitors combined with PD-1 antibodies is promising in cervical cancer and warrants additional clinical and mechanistic investigations. Compared to the positive drug Dactolisib, FD274 exhibited significant anti-proliferation of AML cell lines (HL-60 and MOLM-16 with IC values of 0.092
- | Aliqopa (copanlisib) / Bayer
Journal: Protein Tyrosine Phosphatase Non-Receptor 11 (PTPN11/Shp2) as a Driver Oncogene and a Novel Therapeutic Target in Non-Small Cell Lung Cancer (NSCLC). (Pubmed Central) - Jul 18, 2023
The SHP2 inhibitor, in combination with the PI3K targeting therapy copanlisib, showed no significant difference in tumour development in vivo; however, this significantly prevented MAPK pathway induction in vitro (p < 0.0001). PTPN11/Shp2 demonstrated the in vitro features of a driver oncogene and could potentially sensitize NSCLC cells to PI3K inhibition and inhibit MAPK pathway activation following PI3K pathway targeting.
- | Journal: Xanol Promotes Apoptosis and Autophagy and Inhibits Necroptosis and Metastasis via the Inhibition of AKT Signaling in Human Oral Squamous Cell Carcinoma. (Pubmed Central) - Jul 18, 2023
Finally, we demonstrated that xanol exerted anticancer effects on tumorigenicity associated with its transformed properties. Taken together, these findings demonstrate the anticancer effects and biological mechanism of action of xanol as an effective phytomedicine for human OSCC.
- | Preclinical, Journal: Inhibition of AXL receptor tyrosine kinase enhances brown adipose tissue functionality in mice. (Pubmed Central) - Jul 18, 2023
In line with this, both constitutive Axl deletion as well as inducible adipocyte-specific Axl deletion protect animals from diet-induced obesity concomitant with increases in energy expenditure. Based on these data, we propose AXL receptor as a target for the treatment of obesity.
- | LY294002 / Eli Lilly
Journal: Gastrodin relieves cognitive impairment by regulating autophagy via PI3K/AKT signaling pathway in vascular dementia. (Pubmed Central) - Jul 18, 2023
Meantime, we found that LY294002, a PI3K inhibitor, substantially abolished GAS-mediated neuroprotection. These results revealed that the effects of GAS on VaD are related to stimulating PI3K/AKT pathway-mediated autophagy, suggesting a potentially beneficial therapeutic strategy for VaD.
- | Journal: 1-Methoxyerythrabyssin II Induces Autophagy in Leukemia Cells via PI3K/Akt/mTOR Pathways. (Pubmed Central) - Jul 17, 2023
In vitro assays further demonstrated that 1-methoxyerythrabyssin II promoted autophagy and suppressed cell proliferation by inhibiting the PI3K/Akt/mTOR pathway in leukemic cells. This discovery will contribute to the development of novel therapeutics and prophylactics against leukemia.
- ||||| Venclexta (venetoclax) / Roche, AbbVie, Walter and Eliza Hall Institute
Clinical: Respectfully disagree, we have also quite some examples of huge PFS improvement with OS detriment. Detriment, not even no effect, but pernicious effect. Examples: PI3K inhibitors in CLL/FL, venetoclax in MM. Can't guarantee you're benefiting patients just because PFS is extended (Twitter) - Jul 17, 2023
- | Journal: Pachymic acid protects against Crohn's disease-like intestinal barrier injury and colitis in miceby suppressingintestinal epithelial cell apoptosis via inhibiting PI3K/AKT signaling (Pubmed Central) - Jul 17, 2023
This discovery will contribute to the development of novel therapeutics and prophylactics against leukemia. PA ameliorates TNBS-induced intestinal barrier injury in mice by antagonizing apoptosis of intestinal epithelial cells possibly by inhibiting PI3K/AKT signaling.
- | Preclinical, Journal: Role of insulin-like growth factor 1 (IGF1) in the regulation of mitochondrial bioenergetics in zebrafish oocytes: lessons from in vivo and in vitro investigations. (Pubmed Central) - Jul 17, 2023
The IGF1-depleted follicles showed elevated superoxide anions, subdued steroidogenic potential, and attenuated G2-M1 transition. In summary, this study highlights the importance of IGF1 signaling in oocyte bioenergetics prior to resumption of meiosis.
- | Lynparza (olaparib) / Merck (MSD), AstraZeneca, Aliqopa (copanlisib) / Bayer
Enrollment change, Trial completion date, Trial withdrawal, Trial primary completion date: NRG-GY029: Comparing Standard of Care Chemotherapy Treatment to the Combination of Copanlisib and Olaparib for Recurrent Platinum Resistant Ovarian Cancer That Has Progressed Through PARP Inhibitor Therapy (clinicaltrials.gov) - Jul 17, 2023
P2, N=0, Withdrawn, Sponsor: National Cancer Institute (NCI)
In summary, this study highlights the importance of IGF1 signaling in oocyte bioenergetics prior to resumption of meiosis. N=96 --> 0 | Trial completion date: Jul 2024 --> Mar 2023 | Suspended --> Withdrawn | Trial primary completion date: Jul 2024 --> Mar 2023
- | Journal: Network pharmacology, molecular docking and experimental verification help unravel chelerythrine's potential mechanism in the treatment of gastric cancer. (Pubmed Central) - Jul 15, 2023
Finally, western blotting results showed that CHE downregulated the expression of the PIK3CA protein and inhibited the activation of the PI3K/AKT signaling pathway. Therefore, we concluded that CHE inhibited GC cell proliferation and migration and induced cell cycle arrest and apoptosis by targeting the PIK3CA protein to inhibit the PI3K/AKT pathway activity.
- | Aliqopa (copanlisib) / Bayer
Journal: Model-informed approach to support Pediatric Dosing for the Pan-PI3K Inhibitor Copanlisib in Children and Adolescents with Relapsed/Refractory Solid Tumors. (Pubmed Central) - Jul 14, 2023
An established adult population PK model was extended to incorporate an allometrically-scaled effect of body surface area and confirmed that the copanlisib maximum tolerated dose (MTD) of 28 mg/m was appropriate to achieve uniform copanlisib exposures across the investigated pediatric age range and consistent exposures to historical data in adult cancer patients. The model-informed approach successfully supported and confirmed the copanlisib pediatric dose recommendation.
- | Journal: Network pharmacology, molecular docking and experimental verification of the mechanism of huangqi-jixuecao herb pair in treatment of peritoneal fibrosis. (Pubmed Central) - Jul 12, 2023
Data from in vivo and in vitro validation experiments collectively showed that HQJXCHP delays the PF process through inhibiting PI3K/Akt, IL-17, TNF and TLR signaling pathways. Overall, our findings highlight the successful application of network pharmacology theory to provide a scientific basis for clinical utility of HQJXCHP against PF.
- | Journal: PSMC4 promotes prostate carcinoma progression by regulating the CBX3-EGFR-PI3K-AKT-mTOR pathway. (Pubmed Central) - Jul 12, 2023
In conclusion, PSMC4 could regulate the PCa progression by mediating the CBX3-EGFR-PI3K-AKT-mTOR pathway. These findings provided a new target for PCa treatment.
- | Journal: Seawater pearl hydrolysate inhibits photoaging via decreasing oxidative stress, autophagy and apoptosis of Ultraviolet B-induced human skin keratinocytes. (Pubmed Central) - Jul 12, 2023
The mechanism indicates removing the excessive ROS through increasing the antioxidation of photoaging Hacat cells. Once redundant ROS is eliminated, SPH works to reduce AMPK, increase PI3K-Akt pathway expression, activate mTOR pathway to lowdown autophagy level, and as a result, inhibit apoptosis and aging in photoaging Hacat cells.
- | Opdivo (nivolumab) / BMS, Aliqopa (copanlisib) / Bayer, Yervoy (ipilimumab) / BMS
Biomarker, Enrollment closed, Checkpoint inhibition, IO biomarker, Metastases: Testing the Addition of an Anti-cancer Drug, Copanlisib, to the Usual Immunotherapy (Nivolumab With or Without Ipilimumab) in Patients With Advanced Solid Cancers That Have Changes in the Following Genes: PIK3CA and PTEN (clinicaltrials.gov) - Jul 12, 2023
P1/2, N=102, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Once redundant ROS is eliminated, SPH works to reduce AMPK, increase PI3K-Akt pathway expression, activate mTOR pathway to lowdown autophagy level, and as a result, inhibit apoptosis and aging in photoaging Hacat cells. Recruiting --> Active, not recruiting
- | SL-901 / Menarini
Trial completion, Enrollment change, Trial completion date, Trial primary completion date, Metastases: Study of the PI3K Inhibitor SL-901 in Patients With Advanced Solid Tumors With Advanced Solid Tumors (clinicaltrials.gov) - Jul 12, 2023
P1, N=20, Completed, Sponsor: Stemline Therapeutics, Inc.
Recruiting --> Active, not recruiting Recruiting --> Completed | N=60 --> 20 | Trial completion date: Dec 2023 --> Jun 2023 | Trial primary completion date: Dec 2023 --> May 2023
- || Biomarker, Review, Journal: A narrative review about CDK4/6 inhibitors in the setting of drug resistance: updates on biomarkers and therapeutic strategies in breast cancer. (Pubmed Central) - Jul 12, 2023
Possible approaches to overcome CDK4/6 inhibitors resistance were further discussed. For example, using another CDK4/6 inhibitor, PI3K inhibitor, mTOR inhibitor, or a novel drug.